SEC fundamentals · as filed in 10-Q FY2026, period ended Jun 30, 2026 · updated Aug 29, 2026
as filed in 10-Q FY2026, period ended Jun 30, 2026 · View filings on EDGAR ↗
In its FY2026 report, BIO KEY INTERNATIONAL INC reported total assets of $7.5M, stockholders' equity of $4.3M, and revenue of $1.9M. Every figure below is taken directly from BIO KEY INTERNATIONAL INC's SEC filings: each links to the source document on EDGAR.
Revenue · FY2016–FY2025 · as reported
as of Jun 30, 2026 · 10-Q
10-Q (quarterly) · period ended Jun 30, 2026
| Revenue | $1.9M | Revenue | source ↗ |
| Net Income | -$576,852 | Net | source ↗ |
| Operating Income | -$529,405 | Operating | source ↗ |
| Gross Profit | $1.7M | Gross | source ↗ |
| Cost of Revenue | $245,951 | Cost | source ↗ |
| R&D Expense | $640,418 | Research | source ↗ |
10-Q (quarterly) · period ended Jun 30, 2026
| EPS (diluted) | — | — | source ↗ |
| EPS (basic) | $-0.56 | Earnings | source ↗ |
| Shares Outstanding | 1.4M | Entity | source ↗ |
| Cash from Operations | -$845,749 | Net | source ↗ |
| Cash from Financing | $7,660 | Net | source ↗ |
| Cash from Investing | $0 | Net | source ↗ |
Form 4 open-market activity, last 180 days
No open-market Form 4 transactions filed in the last 180 days.
11 of 452 annual fact-keys were materially restated between filings: what BIO KEY INTERNATIONAL INC first reported differed from what it later filed. We keep every vintage of every annual figure, each keyed to its EDGAR accession.
See each original-vs-restated value, and query any company as of any past date, with the point-in-time API.
As-of fundamentals at any past date are on Free too, up to 10 lookups a day; Analyst removes that cap and adds the original-vs-restated detail behind the counts above, plus MCP access for your own agents, across the whole SEC universe.
Not investment advice. Figures are shown as filed with the SEC; see the EDGAR source links for the original documents. Data may lag the latest filing.